Sun Genomics Appears in 0.4% of AI Answers. Here's Our Five-Step Plan to Improve Its AI Visibility.

Answer Capsule

In November 2026, Sun Genomics appeared in 2 of 493 AI answers included in the Gut Health and Probiotics benchmark (0.41%). It received 0 recommendations (0.00%), with 0 Top 3 placements and 0 first-place recommendations. A mention means the company appeared in an answer; a recommendation means the answer affirmatively endorsed it.

Our plan compares the company with its competitors, checks conflicting AI claims against reliable sources, and identifies website pages, third-party sources and buyer questions to address. The historical results show how the figures changed across available months. Different monthly samples limit those comparisons, and conflicting AI claims require verification before corrections are proposed.

Current AI visibility

Questions This Section Answers

• How do Sun Genomics mentions, recommendations and placements compare with its Gut Health and Probiotics peers?

Sun Genomics recorded 2 mentions (0.41%) and 0 recommendations (0.00%) across 493 answers included in the benchmark. Top 3 placements numbered 0; first-place recommendations numbered 0. Framing among its mentions was 0 positive, 2 neutral and 0 negative.

Sun Genomics appears in the conversation but is not yet part of the recommendation set. Two mentions with no endorsements means the brand is being seen without being chosen, which is a different problem from being invisible. The gap to close is endorsement, not awareness alone.

Because the mentions carry neutral framing, there is no negative story to repair. The practical starting point is to understand what those two answers said and which questions produced them, then set an endorsement goal grounded in that baseline rather than in the leaders' rates.

What changed since last month

Questions This Section Answers

• How did Sun Genomics counts and coverage differ across the available monthly snapshots?

From October 2026 to November 2026, Sun Genomics' mention count rose from 0 to 2, while its recommendation count stayed at 0. The recommendation rate was 0.00% and 0.00% respectively.

The monthly record shows mentions returning after several months at zero, while recommendations stayed at zero throughout. That is an observed movement in the selected samples, not evidence that anything on the brand side changed. The samples differ between months, so the comparison is descriptive only.

The useful reading is that visibility can reappear without endorsement following. We would treat the recent mentions as a starting observation and watch whether they persist before drawing any conclusion about direction.

Step 1. Measure

Questions This Section Answers

• What should the agency measure and verify first for Sun Genomics?

AI answers contained 0 conflicting claims about Sun Genomics: 0 critical, 0 high, 0 medium, 0 low. Of these, 0 were rated critical or high priority; the critical claims are included in that total. These ratings help prioritize fact-checking. They do not establish that a company or publisher made an error.

No conflicting claims about Sun Genomics were recorded in the captured answers, so there is nothing to correct and no fact-check queue to open. That is a clean starting position, and it means effort can go toward earning endorsement rather than defending the brand.

We would still build a visibility scorecard that tracks mentions, endorsements and placement separately, so the client can see which measure moves. A short list of claims worth verifying against primary sources would sit alongside it, ready if disputes appear later.

Step 2. Make the website consistent

Questions This Section Answers

• Which recorded claim differences about Sun Genomics should be verified before proposed page edits?

No results are available for this part of the analysis.

Both columns quote AI answers, not verified company facts. Resolve the entity, date and source before deciding whether a correction is warranted; different dates can explain an apparent conflict.

There are no disputed topics to resolve for this company in the current evidence, so page work should begin with verification rather than correction. We would confirm the brand's own product facts, audience and positioning from primary sources before drafting anything.

Conditional page briefs would then be prepared only for pages the client confirms are current and relevant. If a conflict does surface later, the entity, date and source get checked first, since differing dates can explain an apparent disagreement without anyone being wrong.

Step 3. Align the external narrative

Questions This Section Answers

• Which cited third-party pages are relevant to fact review for Sun Genomics?

These pages were selected because they relate to the company in the captured answers. Their current contents still need checking before any correction request. A page linked to a conflicting claim is not necessarily its cause, and the same answer may contribute to more than one row.

Three third-party pages were selected for review because they appeared alongside the company in captured answers. Citation alone does not show that a page influenced an answer, and none of these pages is linked to a conflicting claim. Their current contents still need checking.

We would read each page against approved brand facts and decide whether an evidence-backed update request is justified. Where the page is accurate and simply does not cover the brand, the better move may be no request at all.

Step 4. Optimize priority company pages

Questions This Section Answers

• Which observed Sun Genomics website pages should receive review briefs?

The company's website was cited 3 times across 2 distinct page addresses; the table shows 2 pages selected for review. Zeros in the answer columns mean no matching answers were recorded. A cited page is not automatically a page that accompanied a recommendation.

The company's own pages were cited in captured answers but never in answers that recommended the brand. That pattern suggests the pages are being read without carrying an endorsement, though the evidence cannot confirm why.

Page briefs would use approved facts and real audience questions, applied to the pages the client confirms are live. We would check existing coverage before proposing anything new, and treat a cited page as an opportunity to strengthen rather than proof of a gap.

Step 5. Publish around buyer questions

Questions This Section Answers

• Which observed buyer questions support content briefs for Sun Genomics?

These are recorded answer observations, not search volume, verified demand, or proof of missing website content.

The recorded questions centre on kids' probiotics and gut health supplements for women, and the brand was mentioned in answers to both without being recommended. These are answer observations, not search volume or proof that the website lacks coverage.

We would check what the site already says on these topics, then draft buyer-question content that answers directly and gives a reason to choose the brand. Briefs would be written for the client's review before any publishing decision.

Our 90-day action plan

Questions This Section Answers

• How should the agency sequence the proposed Sun Genomics work and judge completion?

The first month produces a baseline scorecard, a scoped fact-review register and a shortlist of pages and sources, each with an owner and review status. Nothing is corrected in this phase; verification comes first.

The second month turns confirmed facts into approved page briefs and, where justified, publisher requests, with edits, no-change decisions and responses recorded separately. The third month adds buyer-content briefs and a fresh scorecard. Completed work is reported apart from measured answer outcomes, with comparability limits stated.

Methodology

Questions This Section Answers

• How are Sun Genomics answer metrics and citation populations defined?

This report covers 2026-11. The exact dates when the original AI answers were collected have not been verified. The visibility rates use 493 answers that met the benchmark's inclusion rules. A company is recommended only when the answer both endorses it and uses positive wording. Top 3 and first-place counts are part of those recommendations, not extra recommendations.

An answer can mention or recommend several companies, so company counts cannot be added to find the number of distinct answers. The net sentiment score is positive minus negative mentions, divided by all company mentions; it describes answer wording, not customer satisfaction.

The wider citation analysis covers 800 captured answers and 6124 appearances of cited URLs. Citation appearances across all captured answers differ from the number of benchmark answers citing a page and the number that also recommend a company. The current contents of cited pages and disputed company claims still need independent verification.

Monthly sample coverage:

The answer samples differ between months. These comparisons show how the recorded results changed; they do not establish why they changed.

Recommendations require both an endorsement and positive wording, and placements sit inside recommendations rather than adding to them. An answer can cover several companies, so counts cannot be summed into distinct answers. Sentiment describes answer wording, not customer satisfaction.

The collection dates of the original answers are unverified, and the monthly samples differ, so comparisons show what was recorded rather than why. Cited pages and any disputed claims still need independent checking.

Our first three priorities

First, verify the brand's core product facts and audience from primary sources, since every later step depends on approved facts. Second, review the three selected third-party pages and the company's own cited pages to decide which, if any, warrant an evidence-backed request or a page brief.

Third, prepare buyer-question content for the kids' and women's topics, checking existing coverage first. Throughout, we would track mentions and endorsements as separate measures so progress is judged on endorsement rather than visibility alone.